Podcasts about Heart failure

This month KYW Newsradio's Rasa Kaye and Deborah Heart and Lung center Cardiologist Geurys Rojas-Marte, MD discuss how individuals can prevent or manage risk factors for heart failure. They also talk about the latest advancements in heart failure treatment at any stage.

In this Healthed lecture, Dr Robert Hungerford describes when heart failure should be suspected, how it can be assessed and diagnosed, and the practicalities of initiating and intensifying treatment in keeping with the latest evidence-based, best practice guidelines. In addition, Dr Hungerford will describe how these patients should be monitored and managed long-term and when they need to be referred on, all with the aim of improving not only mortality but also their quality of life.See omnystudio.com/listener for privacy information.

Heart failure remains one of the most urgent challenges in health care, affecting millions of individuals and imposing a significant burden on families and the broader health system. Although guideline-directed medical therapy (GDMT) has been shown to improve clinical outcomes and reduce hospitalizations, adoption of these therapies remains suboptimal nationwide. Addressing this treatment gap is essential not only for enhancing survival and quality of life but also for mitigating the rising economic impact of heart failure as its prevalence continues to increase. Gluckman also led the session “Addressing Underuse of Guideline-Directed Medical Therapy in Heart Failure” at the July 9 Institute for Value-Based Medicine® (IVBM) event in Garden Grove, CA, where he addressed the need for integrated approaches to drive sustainable, system-level change in cardiovascular care. On this episode of Managed Care Cast, Ty Gluckman, MD, MHA, FACC, FAHA, FASPC—a practicing cardiologist at Providence Heart Institute in Portland, Oregon, and medical director of Providence's Center for Cardiovascular Analytics, Research, and Data Science—discusses strategies to improve GDMT implementation. The conversation explores opportunities for payers and providers, the potential of remote patient monitoring and digital health tools, and the role of value-based care models in supporting optimal therapy. Emphasis is placed on the importance of aligning clinical guidelines with managed care policies to drive meaningful improvements in patient outcomes.

Testosterone TEST IS BEST - Bodybuilding Podcast ep. 76#bodybuilding #TRT #Muscle #Contestprep #bodybuildingpodcastMy Book:ULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠⁠⁠⁠Daily Text Msg Training 99/month and 1 Hour Phone Call Consult 59 Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast: ⁠⁠⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠⁠Time Stamps:0:00 Ferocious Libido on a steroid cycle of Low Test High Tren - Low Sex Drive on a Cruise4:20 Proviron and Masteron - Libido - Acne - Prostate - Talking about Masteron Enanthate8:12 Getting off Gear Due to Health Problems - Losing alot of Muscle10:52 Alot of Big Guys like the way 1000mg Testosterone Per Week Feels, and don't like to go below that.15:34 DHEA and Pregnenolone20:45 1000mg of Testosterone per week Every Single Big Guy I Know Says it was the Biggest Game Changer24:03 Heart Failure and Wants to Cycle Steroids26:00 Left Ventricular Hypertrophy Steroid Heart Growth is Reversible27:33 Winstrol Optimal Cycle Duration and In Depth Real World Use of this Incredible Hormone for Bodybuilding30:17 Cutting Cycle on High Testosterone33:42 Masteron and Primobolan Shortage - What Other hormones can replace them35:55 Anavar Big Pharma - Viagra Sildenafil - Glp1 Agonists - Ozempic 39:11 How to Tell if you have GYNO Bitch TITS - Ronnie Coleman won the 1998 Mr Olympia with Severe GYNO43:00 What Foods to Eat before training first thing in the morning - PROATS whey protein and oats45:55 Best Exercises For Muscle Mass for Each Bodypart - Barbell Pause Bench Press for Chest48:00 Dumbell Row Explanation for massive gains51:53 Trenbolone Long and Short Esters - PARABOLAN Trenbolone hexahydrobenzylcarbonate GH15 god of hormones56:35 Testosterone and Primobolan Ratio - Sensitive to Estrogen from Testosterone and DbolThis Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2024:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) (0:00 – 4:09)Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) (4:10 – 9:28)Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) (9:29 – 14:23)Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH) (14:24 – 20:28)Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BALANCE) (20:29 – 23:59)And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (24:00 - 25:23)Calling keen trainees!Trainees, med students, residents: The Rounds Table and Trial Files (https://trialfiles.substack.com/) are looking for keen individuals to support our efforts.Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

This episode covers:  Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

“When a patient comes in for a routine outpatient echo, we’ll be able to help with diagnosis and reduce the misdiagnosis at that point, number one,” Ultromics’ Founder and CEO Ross Upton explains to Bloomberg Intelligence analyst Matt Henriksson about the initial benefits of EchoGo for heart failure and cardiac amyloidosis. In this episode of the Vanguards of Health Care podcast, Upton also delves into the future of diagnosing and treating heart failure with artificial intelligence, saying it can additionally “really accurately phenotype them, and so the clinician would understand after the echo is done what treatments or what next diagnostic tests the patient needs, and they would understand it there and then without having to go through and try and figure out the pieces of the puzzle.” Also tune in to learn how Ultromics plans to use to recently announced Series C financing as it commercializes EchoGo for heart failure and cardiac amyloidosis.See omnystudio.com/listener for privacy information.

In this focus issue on Heart Failure in Practice, JACC Editor-in-Chief Dr. Harlan Krumholz examines how contemporary research continues to refine and at times challenge our understanding of heart failure management. This week's episode features a first-of-its-kind trial on dual therapy with SGLT2 inhibitors and MRAs, new real-world data on heart failure with improved EF, and sobering insights into what happens when foundational therapies are withdrawn. Also explored: sex-specific risks in genetic cardiomyopathies, the limitations of standard stroke prediction tools, and the case for modernizing ICD eligibility criteria. As always, the episode concludes with a synthesized summary of key takeaways for clinicians.

**NEW PODCAST WITH NEW CONTENT** Zak's new show, the RD Exam Ready Podcast will be featuring NEW EPISODES of study material! Listen in for a featured episode about the pathology and MNT for Heart Failure! Subscribe to the RD Exam Ready Podcast.Watch on Youtube IG: @RDexamready

Join us for a conversation with a heart failure nurse leader who's been at the forefront of remote monitoring. In this episode, we explore the clinical value of CardioMEMS in managing heart failure, especially for patients who appear stable but are at high risk for decompensation—along with insights on the expanded National Coverage Determination and the future of cardiovascular care.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Impact of Pharmacist Telehealth Comanagement for Heart Failure: A Nonrandomized Controlled Study.

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we cover sympathetic crashing acute pulmonary edema (SCAPE). To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play 

In this episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz introduces the journal's new design and highlights key studies from the July 29, 2025 issue. Topics include the under-expansion analysis of the ACURATE NEO2 valve, the impact of tirzepatide in obesity-related HFpEF, the effects of private equity ownership on heart failure care, and evolving strategies for managing multivalve disease.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for July 7-13, 2025: FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More Finerenone (Kerendia) was approved on July 14, 2025, to reduce cardiovascular death and heart failure hospitalizations in adults with HFmrEF or HFpEF, based on data from the FINEARTS-HF trial. Baxdrostat Meets Efficacy Endpoint in Phase 3 Trial for Resistant Hypertension In the phase 3 BaxHTN trial, baxdrostat significantly reduced systolic blood pressure in patients with resistant hypertension, supporting its potential as a first-in-class aldosterone synthase inhibitor. FDA Approves Updated VARIPULSE Platform Irrigation Flow Rate for Heart Disease The FDA approved an updated irrigation flow rate for the VARIPULSE Platform, which has been used in over 10,000 procedures with a reported neurovascular adverse event rate of less than 0.5%. Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism Palopegteriparatide showed durable 3-year improvements in biochemistries, kidney function, and quality of life across all forms of hypoparathyroidism in the phase 3 PaTHway trial. FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment Taladegib received Orphan Drug Designation on July 16, 2025, as a potential treatment for idiopathic pulmonary fibrosis, currently being studied in the phase 2b WHISTLE-PF trial.

This activity was supported by an educational grant from Bristol Myers Squibb. Please go to ⁠academiccme.com/HFPod and complete the evaluation to receive your CE/CME Credit. Credit is available through May 15, 2026.

Send us a textIn this episode, CMMI Director Abe Sutton shares his unique journey from the private sector back to government service and reveals how he's rapidly transforming Medicare through innovative payment models. Sutton discusses the newly launched WISER (Wasteful and Inappropriate Service Reduction) model, which leverages AI technology to reduce fraud and waste in Medicare, and the upcoming ASM (Ambulatory Specialty Model) targeting heart failure and lower back pain. The conversation explores CMMI's 2025 strategy focused on evidence-based prevention, patient empowerment, and choice and competition, while addressing how emerging technologies like generative AI are creating unprecedented opportunities to streamline healthcare administration and improve patient outcomes. Sutton also reveals how he spent four years during his "off season" developing a comprehensive roadmap for healthcare innovation that he's now implementing at warp speed.Links:WISeR (Wasteful and Inappropriate Service Reduction) model: https://www.cms.gov/priorities/innova...ASM (Ambulatory Specialty Model): https://www.cms.gov/priorities/innova...CMMI's 2025 Strategy Focus: https://www.cms.gov/priorities/innova...Learn how AI can amplify your care coordination team by visiting https://link.careco.ai/HTRKQsTimestamps:00:00:00 - Introduction and Welcome00:00:37 - Why Leave Private Sector for Government Service00:09:16 - AI and Technology's Impact on Healthcare Innovation00:17:49 - WISER Model Introduction and Goals00:30:45 - Food Policy and Making America Healthy Again00:34:08 - ASM Model for Heart Failure and Lower Back Pain00:38:31 - Four Years of Preparation During "Off Season"

Heart failure is one of the most complex and high-risk conditions med-surg nurses manage. In this episode, the co-hosts offer their personal nursing tips to help you monitor, educate, and care for patients with heart failure. Also, find out how Marcela's first neighborhood yard sale went and hear the latest update on Sydney's wedding planning.  MEET OUR CO-HOSTS Samantha Bayne, MSN, RN, CMSRN, NPD-BC is a nursing professional development practitioner in the inland northwest specializing in medical-surgical nursing. The first four years of her practice were spent bedside on a busy ortho/neuro unit where she found her passion for newly graduated RNs, interdisciplinary collaboration, and professional governance. Sam is an unwavering advocate for medical-surgical nursing as a specialty and enjoys helping nurses prepare for specialty certification.    Kellye' McRae, MSN-Ed, RN is a dedicated Med-Surg Staff Nurse and Unit Based Educator based in South Georgia, with 12 years of invaluable nursing experience. She is passionate about mentoring new nurses, sharing her clinical wisdom to empower the next generation of nurses. Kellye' excels in bedside teaching, blending hands-on training with compassionate patient care to ensure both nurses and patients thrive. Her commitment to education and excellence makes her a cornerstone of her healthcare team.   Marcela Salcedo, RN, BSN is a Floatpool nightshift nurse in the Chicagoland area, specializing in step-down and medical-surgical care. A member of AMSN and the Hektoen Nurses, she combines her passion for nursing with the healing power of the arts and humanities. As a mother of four, Marcela is reigniting her passion for nursing by embracing the chaos of caregiving, fostering personal growth, and building meaningful connections that inspire her work.   Eric Torres, ADN, RN, CMSRN is a California native that has always dreamed of seeing the World, and when that didn't work out, he set his sights on nursing.  Eric is beyond excited to be joining the AMSN podcast and having a chance to share his stories and experiences of being a bedside medical-surgical nurse.   Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a clinical educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!   Sydney Wall, RN, BSN, CMSRN has been a med surg nurse for 5 years. After graduating from the University of Rhode Island in 2019, Sydney commissioned into the Navy and began her nursing career working on a cardiac/telemetry unit in Bethesda, Maryland.  Currently she is stationed overseas, providing care for service members and their families.  During her free time, she enjoys martial arts and traveling.   

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Louis-Marie Desroche from Reunion Island. They discuss his study that concluded - "Relying solely on CMR could lead to missed diagnoses and undertreatment. CMR should be integrated with other diagnostic tools to optimise care in this population". If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/early/2025/03/26/heartjnl-2024-325419  

Wtih Robert Mentz, Duke University, North Carolina - USA, and Cornelia Margineanu University of Medicine and Pharmacy Carol Davila, Bucharest - Romania.  A focused discussion and an update on the latest developments in iron deficiency — a journey from definition to outcomes through available therapeutic options. Not to be missed!

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. In this episode, Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, discusses various health topics aimed at improving heart health and overall well-being. He emphasizes the importance of salt reduction, highlighting that the World Health Organization recommends consuming less than one teaspoon of salt daily. Research indicates that potassium-based salt substitutes can significantly reduce stroke and death risks. The podcast also covers bone health, clarifying that vitamin E may not be beneficial for bone density, while vitamins D and K2 are suggested for better bone and vascular health.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Joan Guzmán-Bofarull, and senior author, Marta Farrero, both of the Hospital Clinic de Barcelona in Spain. They join to discuss their paper, “Regional differences in primary graft dysfunction: A report from the international consortium on PGD.” The discussion explores: The international consortium on PGD, the composition of the study, and the practices of the included countries in the United States, Canada, and Europe Hypotheses on why the study shows better 30-day and 1-year outcomes in the United States Considerations transplant centers can take regarding recipient management and donor heart selection For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode from Colorado ACEP, we learn about the EM approach to right heart failure and pulmonary hypertension.

In this episode of Better Edge, Sadiya S. Khan, MD, discusses the AHA's groundbreaking PREVENT-HF paradigm, which aims to implement a risk-based approach to heart failure prevention like other established methods for heart attack and stroke. Dr. Khan covers the alarming trends of heart failure prevalence in the U.S., the importance of early detection, and the integration of traditional and non-traditional risk factors in clinical practice. She also highlights how innovative strategies and emerging technologies like AI are helping shape the future of heart failure risk assessment and patient care.

Heart failure is a growing problem with at least half a million Australians living with it at any given time - and more than 67,000 new cases diagnosed each year. Heart failure is responsible for approximately 61,000 deaths annually, numbers that are likely to increase with the growing and ageing population. Advocates say they are worried a lack of awareness about the condition is leaving Australians vulnerable. Deborah Groarke spoke with Professor Andrew Sindone, who is the Director of the Heart Failure Unit and Department of Cardiac Rehabilitation at Sydney's Concord Hospital

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association of Race With Risk of Incident Cardiovascular Disease, Coronary Heart Disease, Heart Failure, and Stroke.

A Northwestern Medicine clinical trial led by Rod Passman, MD, could improve the way we care for millions of people with atrial fibrillation, but it is facing an unexpected challenge. There has been a pause in federal funding to Northwestern University that could impact this study's progress. While the trial has not been ordered to stop, all National Institutes of Health funding to Northwestern University has been frozen, raising questions about how long this potential life-saving work can go on without a resolution.  

In this debut episode of JACC This Week with Editor-in-Chief Dr. Harlan Krumholz, we explore groundbreaking studies and timely insights from the July 1st issue. Highlights include the impact of wildfire smoke on heart failure risk, new hemodynamic data on mechanical circulatory support in cardiogenic shock, and sobering cardiovascular mortality trends over the past 25 years. Plus, updates on aspirin use, cognitive impairment in CVD, ACC/AHA performance measures, and a leadership reflection from ACC President Dr. Christopher Kramer.

In this episode of Medicine Grand Rounders, Dr. Sanjeeb Bhattacharya - Director of the HFpEF clinic and Associate Program Director of the HVTI heart failure fellowship - goes over various clinical presentations of heart failure with preserved ejection fraction. Moderated by: Yasmine K. Elghoul, MD

Send us a textWelcome back Rounds Table Listeners! Today we have another special episode— Trial Files turns two years old this June, and we're celebrating with an episode summarizing the Top 5 RCTs in the Trial Files catalogue to date. Dr. Mike Fralick takes us through five trials in 15 minutes. Here we go!1. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (0:00 - 3:08)2. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia (3:09 - 5:37)3. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (5:38 - 8:33)4. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (8:34 - 11:22)5. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (11:23 - 13:23)Happy 2nd Birthday, Trial Files!A free monthly newsletter on practice-changing trials, delivered straight to your inbox-- sign up at https://trialfiles.substack.com/ (13:24 - 14:19)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

This month on Episode 73 of Discover CircRes, host Cindy St. Hilaire highlights articles featured in the May 23rd and June 6th issues of Circulation Research. This Episode also includes a discussion with Dr Jae Min Cho and Tzung Hsiai, about their study, Habitual Exercise Modulates Neuroimmune Interaction to Mitigate Aortic Stiffness.   Article highlights: Interorgan Crosstalk in Heart Failure and Cardiometabolic Diseases: A Compendium He, et al. NEP in Placental EVs Triggers Hypertension in PE Dennis, et al. FoxO1-zDHHC4-CD36 S-Acylation Axis in Diabetes

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Nikil Prasad, MD, a cardiology fellow in the Columbia University Medical Center in New York, to discuss the paper, “Can the grading of mild cardiac allograft vasculopathy be further refined? An angiographic and physiologic assessment of heart transplant recipients with ISHLT CAV 1.” The discussion explores: The study's subdivisions of CAV grade 1 into CAV 1a and CAV 1b, based on the degree of coronary stenosis Differing clinical information provided by different methods of CAV screening: reduced myocardial blood flow reserve vs angiographic grading Limitations in implementing PET-based CAV assessments at various centers, and how transplant programs can use combined testing data For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:The emerging role of mineralocorticoid receptor antagonists in HF careFinerenone's efficacy in reducing composite cardiovascular death and worsening HF events Why safety must be monitored, especially considering hyperkalemia riskWhere HF guideline recommendations lack compared with the current evidence PresenterTy J. Gluckman, MD, MHAMedical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)Providence Heart InstituteProvidence Health SystemPortland, OregonProgram page: https://bit.ly/448XcH0

Each year, more than 800,000 Americans suffer a heart attack and many of those who survive are left with irreversible scarring and the slow progression towards heart failure. In this episode, Edward Thorp, PhD, explains how his team is exploring immune cells that influence the heart's ability to heal after such injuries. In Thorp's lab, they are uncovering fundamental molecular mechanisms by which the immune system regulates wound repair, reduces inflammation and regenerates tissue. 

Welcome back to this week's Friday Review where I can't wait to share with you the best of the week!     I'm looking forward to reviewing:     Magic Molecule (product review) Four Thousand Weeks (book review) Autoimmune Disease & Heart Failure (research) Collagen & Joint Support (research)     For all the details tune into this week's Cabral Concept 3416 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3416 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In this episode, host Mitsuaki Sawano, MD, is joined by Dr. Shoichiro Yatsu, MD, to discuss his sub-analysis of the ADVENT-HF trial, recently published in JACC: Heart Failure. The study investigates the effects of peak-flow-triggered adaptive servo-ventilation (ASVPF) on left ventricular (LV) structure and function in patients with heart failure and sleep-disordered breathing (SDB). Compared to earlier studies using different ASV algorithms, ADVENT-HF highlights the safety and clinical value of ASVPF, showing meaningful improvements in sleep quality, symptoms, and quality of life. Dr. Yatsu also shares insights from managing legacy trial data collected over more than a decade.

This week is Heart Rhythm Awareness Week, a national campaign focusing on educating the public about heart rhythm disorders, particularly atrial fibrillation. In Ireland, one in four deaths are caused by heart disease and stroke each year For more Prof. Mark Dayer, Head of Heart Failure and Consultant Cardiologist at the Mater Private in Dublin.

In this episode, Dr. Valentin Fuster discusses groundbreaking research validating the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) as a powerful real-world predictor of heart failure outcomes using advanced machine learning on outpatient data. Emphasizing the critical importance of patient-reported health status, he highlights that listening to patients remains essential even in an era dominated by AI-driven medicine.

In this piece we discuss the intricacies of right heart failure, the differences between the right and left ventricles, and the challenges of early detection and monitoring. With a focus upon research we discuss the Swan-Ganz IQ pulmonary artery catheter, with the FastCCO algorithm, from BD Advanced Patient Monitoring. We cover its innovative capabilities, explore its impact on patient care and look particularly at high-risk patients like those with pulmonary hypertension and LVADs. The episode highlights the importance of new monitoring techniques, future research directions, and the promise of continuous data in improving right ventricular function diagnosis and treatment. Presented by Kate Leslie with her guest Joerg Ender, Director of the Department for Anesthesiology and Intensive Care Medicine, Heart Center, Leipzig, Germany. He is second president of the German Society of Anesthesiology and Intensive Care Medicine and former Secretary General of the European Association of Cardiothoracic Anaesthesiologists (EACTA).

For full review of the trials, please visit https://cardiologytrials.substack.com/ Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Some music and sounds in this podcast by @itslucakoala In this BRAND NEW podcast episode — Brittany invites on to chat with her, Kate Safris. She is one of the original founders of ‘Healthy Birthday INC'. She proudly brings awareness to expecting families about the importance of monitoring fetal movement. In this 4 part May podcast series Kate and Brittany deep dive into all things involving child loss, rainbow babies,  the importance of tracking fetal movement….and more. Brittany and Kate will discuss in full detail the @countthekicksus app and how it can help possibly prevent fetal demise. Please learn more about ‘COUNT THE KICKS' and you can download the FREE app today to track your babies movement while in utero.  Please enjoy episodes 1, 2, and 3 are out now! Episode 4 to drop soon. Discussed in this episode — Why wasn't Emma's heart failure caught sooner? : Kate explains — The shock of Kate and husband learning about their daughters' fate — Overcoming grief & loss as a family — Kate begins to discuss her involvement with ‘Count the Kicks' — Kate begins to discuss research and much more regarding monitoring fetal movement while in utero — And much more! AG1: NEXT GEN JUST LAUNCHED! So subscribe today to try the Next Gen of AG1! If you use my link, you'll also get a FREE bottle of AG D3K2, an AG1 Welcome Kit, AND 5 of the upgraded AG1 travel packs with your first order. So make sure to check out DrinkAG1.com/bosbabes to get started with AG1's Next Gen and notice the benefits for yourself.   Get 15% OFF of your FULL Manscaped order by going to manscaped.com and using my code BRITTANY at checkout For all of your furniture needs please be sure to check out Highpoint Furniture Sales. They are fully family owned and operated with 1 great location in the state of North Carolina— visit their showroom In High Point or shop their website highpointfurnituresales.com — they offer white glove delivery and set up services nationwide! For your triad area realty needs please get in touch with Amy Cromer of ‘Cromer Property Group'. Visit her website today for more information www.cromerpropertygroup.com Luca Koala FREE music on Spotify: https://open.spotify.com/album/5kepJgtnHDGsvYiLlKXQ03?si=wZKjnpjvTXSXz-qnBOkX7w

Story at-a-glance New data from the largest clinical trial on this topic shows no improvement in symptoms, hospitalizations, or survival with fluid restriction in chronic heart failure patients Patients who drank more than the advised limit of 1,500 ml had no higher risk of death, hospitalization, kidney injury, or emergency interventions Fluid-restricted patients reported much higher thirst distress, which contributes to stress hormone release, reduced treatment compliance, and increased emotional strain Over-restricting both water and salt leads to dangerously low sodium levels, while getting enough potassium helps your kidneys manage hydration and prevent harmful fluid buildup Researchers recommend giving fluid goals based on your symptoms, medications, and how you feel — this allows you more control and fewer restrictions

Is creatine safe? Does it just make you bloated? Is it only for bodybuilders? You've heard the rumors, now it's time to hear the truth from the world's leading expert on creatine.In this powerful episode of Sweat Success, we sit down with Dr. Richard Kreider, a pioneer in creatine research with over 1,000 published studies and decades of experience shaping sports science. He unpacks the real science behind creatine: its proven benefits for muscle growth, brain health, injury prevention, heart function, and even kids, seniors, and pregnant women.Whether you're a gym owner, high-performance athlete, health-conscious parent, or everyday lifter, this episode will shatter the myths and show you how creatine can radically support your health, performance, and recovery.

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Timing of BP Meds – The BedMed RCT MAPEC https://doi.org/10.3109/07420528.2010.510230 Hygia https://doi.org/10.1093/eurheartj/ehz754 Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501 TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860 Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2 Timing of Blood Pressure Meds Doesn't Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm II Tirzepatide vs Semaglutide SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 III Age-specific Troponins Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308 Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967 IV Return to Play for Gene Positive Phenotype Negative athletes Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013 V Rapid Titration of GDMT in HF STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698 JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020 STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1 AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474 EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

N Engl J Med 1996;334:1349-1355Background Before 1990, the prevailing idea held that the negative inotropy of beta-blockers would harm patients with impaired systolic function. Yet part of the progression of systolic heart failure involved over stimulation of the sympathetic nervous system. Norepinephrine can exert adverse effects on the circulation, both directly and indirectly. Smaller trials of beta-blockers in systolic heart failure found trends for benefit with beta-blockers, however, a mortality benefit had not yet been proven. The U.S. Carvedilol Heart Failure Study aimed to study mortality in patients with heart failure with a reduced ejection fraction.Cardiology Trial's Substack remains free of industry ads because of your support. Thank you. Please consider becoming a free or paid subscriber.Patients The study enrolled 1094 patients with chronic heart failure symptoms for at least 3 months, LVEF ≤ 0.35%, at least 2 months of treatment with diuretics and an angiotensin-converting enzyme (ACE) inhibitor (if tolerated). Treatment with digoxin, hydralazine, or nitrates was permitted but not required.Exclusion criteria were extensive and important to understand. These included any recent major cardiac events or surgery within the previous 3 months, uncorrected valvular disease, active myocarditis, sustained VT or higher degrees of AV block not controlled by pacing, systolic blood pressure of more than 160 or less than 85 mm Hg or diastolic blood pressure of more than 100 mm Hg, clinically significant kidney or liver disease or use of calcium-channel blockers, adrenergic agonists/antagonists, or class IC/III antiarrhythmic agents. Patients receiving β-adrenergic agonists or antagonists (presumably for another indication) were not enrolled.Baseline Characteristics The results of this and other beta-blocker trials in heart failure will be clear. One of the most important points for translating this evidence to patients will be the baseline characteristics. It is vital to understand who these patients were.The mean age was 58 years and approximately 76% were male. Most patients had mild to moderate heart failure, with 53% in NYHA Class II, 44% in Class III, and only 3% in Class IV. The etiology of heart failure was nearly evenly split between coronary artery disease (47%) and nonischemic cardiomyopathy (53%). Patients had significantly impaired cardiac function with a mean LVEF of 0.23. The mean six-minute walk distance ranged from 386 to 390 meters. Hemodynamic parameters were relatively stable, with mean systolic blood pressure of 116 mmHg, and mean heart rate of 83-84 beats per minute. Most patients were receiving standard heart failure therapy at baseline, including digitalis (90-91%), loop diuretics (95%), and ACE inhibitors (95%), while approximately one-third (32%) were on direct-acting vasodilators.Trial Procedures Patients were assessed for eligibility during a 3-week screening period during which exercise capacity was assessed with a 6-minute walk test. Notable was that these were outpatients able to complete a 6-minute walk test. Enrollment was stratified to one of four treatment protocols on the basis of the patients' performance on the exercise test: patients able to walk between 426 and 550 m when tested were assigned to the mild-heart-failure protocol; those able to walk between 150 and 425 m were assigned either to the moderate-heart-failure protocol or to a dose-ranging protocol, depending on the location of the study center; and those able to walk only less than 150 m were assigned to the severe-heart-failure protocol.After this base-line testing, all patients received 6.25mg of carvedilol twice daily for two weeks in an open-label run-in period. Those who tolerated this initial dose were then randomized to receive either placebo (n=398) or carvedilol (n=696) on a double-blind basis, in addition to their usual medications.The allocation ratio (carvedilol:placebo) was 2:1 in the mild and severe heart failure protocols and 1:1 in the moderate heart failure protocol. The dose was gradually increased to target levels of 25-50mg twice daily over 2-10 weeks, followed by maintenance therapy for an additional 6 months (12 months for mild heart failure).Endpoints At the time of trial planning, the original intent was safety. That is, to show that carvedilol did not increase mortality. The original intent was to enroll 1100 patients. As smaller trials on beta-blockers were published, the statistical plan included the possibility of beta-blocker benefit. The trialists therefore planned two sided statistical analysis.Cumulative survival curves were constructed as time-to-first-event plots by Kaplan–Meier survivorship methods and differences between the curves were tested for significance by the log-rank statistic with use of a Cox proportional-hazards regression model (which included the protocol as a covariate).Results Median follow-up was only 6.5 months due to early termination for benefit. The patients mean total daily dose of carvedilol was 45±27 mg. Overall mortality was 7.8% in the placebo group vs. 3.2% in carvedilol group. The relative risk reduction from carvedilol vs placebo was 65% (95% CI, 39-80%; p

We're taking a break this week, but we'll be back next week with a brand-new episode.  Provide superb outpatient care for your patients with HFrEF. Identify underlying causes of heart failure and titrate medications with ease. Dr Michelle Kittleson @MKittlesonMD (Cedars Sinai) breaks down the nuances of treating this common cardiac condition.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction  03:22 Case Presentation: Newly Diagnosed Heart Failure 07:26 Using Physical Exam Findings to Guide Diuresis 11:58 The Four Pillars of Guideline-Directed Medical Therapy for Heart Failure 15:07 Optimizing Therapy and Follow-Up in Heart Failure Patients 22:10 The Benefits of High-Intensity Initiation and Titration of Guideline-Directed Medical Therapy 28:02 Consideration of Other Medications 40:02 Referral to Advanced Heart Failure Specialist 49:11 Optimizing Therapy and Follow-Up 55:33 Conclusion and Book Recommendation Credits Writer and Producer: Deborah Gorth MD, PhD Infographic and Cover Art: Zoya Surani Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Michelle Kittleson MD, PhD Sponsor: Mint Mobile  Get your summer savings and shop premium wireless plans at MINTMOBILE. com/CURB. Sponsor: American College of Physicians Order ACP MKSAP today at acponline.org. Curbsiders Listeners who use promo code  CORECS will receive a MKSAP gift pack with their subscription. Sponsor: Panacea Legal Learn more and schedule your free consultation at Panacea.Legal.